Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer’s Disease

Alvarez, X. A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., et al. (2011). Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology, 18, 59–68.

Angelucci, F., Spalletta, G., di Iulio, F., Ciaramella, A., Salani, F., Colantoni, L., et al. (2010). Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Current Alzheimer Research, 7, 15–20.

Blasko, I., Lederer, W., Oberbauer, H., Walch, T., Kemmler, G., Hinterhuber, H., et al. (2006). Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dementia and Geriatric Cognitive Disorders, 21, 9–15.

Brunoni, A. R., Lopes, M., & Fregni, F. (2008). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. International Journal of Neuropsychopharmacology, 11, 1169–1180.

Christensen, R., Marcussen, A. B., Wortwein, G., Knudsen, G. M., & Aznar, S. (2008). A beta(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Experimental Neurology, 210, 164–171.

Clément, F., & Belleville, S. (2010). Compensation and disease severity on the memory-related activations in mild cognitive impairment. Biological Psychiatry, 68, 894–902. doi: 10.1016/j.biopsych.2010.02.004 .

Covaceuszach, S., Capsoni, S., Ugolini, G., Spirito, F., Vignone, D., & Cattaneo, A. (2009). Development of a non invasive NGF-based therapy for Alzheimer’s disease. Current Alzheimer Research, 6, 158–170.

de Sousa, R. T., van de Bilt, M. T., Diniz, B. S., Ladeira, R. B., Portela, L. V., Souza, D. O., et al. (2011). Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. Neuroscience Letters, 494, 54–56.

Diniz, B. S., & Teixeira, A. L. (2011). Brain-derived neurotrophic factor and Alzheimer’s disease: Physiopathology and beyond. NeuroMolecular Medicine, 13, 217–222.

Diniz, B. S., Reynolds, C. F., I. I. I., Begley, A., Dew, M. A., Anderson, S. J., Lotrich, F., et al. (2014a). Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study. Journal of Psychiatric Research, 49, 96–101.

Diniz, B. S., Sibille, E., Ding, Y., Tseng, G., Aizenstein, H. J., Lotrich, F., et al. (2015). Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Molecular Psychiatry, 20, 594–601. doi: 10.1038/mp.2014.76 .

Diniz, B. S., Teixeira, A. L., Machado-Vieira, R., Talib, L. L., Radanovic, M., Gattaz, W. F., et al. (2014b). Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 69, 845–851.

Diniz, B. S., Teixeira, A. L., Talib, L. L., Mendonca, V. A., Gattaz, W. F., & Forlenza, O. V. (2010). Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World Journal of Biological Psychiatry, 11, 550–555.

Douillard-Guilloux, G., Guilloux, J. P., Lewis, D. A., & Sibille, E. (2013). Anticipated brain molecular aging in major depression. American Journal of Geriatric Psychiatry, 21, 450–460.

Faria, M. C., Gonçalves, G. S., Rocha, N. P., Moraes, E. N., Bicalho, M. A., Cintra, M. T. G., et al. (2014). Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. Journal of Psychiatric Research, 53, 166–172.

Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. British Journal of Psychiatry, 198, 351–356.

Forlenza, O. V., Diniz, B. S., Talib, L. L., Radanovic, M., Yassuda, M. S., Ojopi, E. B., et al. (2010a). Clinical and biological predictors of Alzheimer’s disease in patients with amnestic mild cognitive impairment. Revista Brasileira de Psiquiatria, 32, 216–222.

Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Ojopi, E. B., Talib, L. L., Mendonca, V. A., et al. (2010b). Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World Journal of Biological Psychiatry, 11, 774–780.

Huijbers, W., Mormino, E. C., Schultz, A. P., Wigman, S., Ward, A. M., Larvie, M., et al. (2015). Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 138, 1023–1035. doi: 10.1093/brain/awv007 .

Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., et al. (2007). BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. Journal of Psychiatric Research, 41, 387–394.

Li, G., Peskind, E. R., Millard, S. P., Chi, P., Sokal, I., Yu, C. E., et al. (2009). Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS ONE, 4, e5424.

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology, 34, 939–944.

Miller, S. L., Fenstermacher, E., Bates, J., Blacker, D., Sperling, R. A., & Dickerson, B. C. (2008). Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. Journal of Neurology, Neurosurgery and Psychiatry, 79, 630–635.

Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., et al. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nature Medicine, 15, 331–337.

Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005). Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. Journal of Neurochemistry, 93, 1412–1421.

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., et al. (2001). Current concepts in mild cognitive impairment. Archives of Neurology, 58, 1985–1992.

Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., & Winslow, J. W. (1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron, 7, 695–702.

Rockenstein, E., Ubhi, K., Pham, E., Michael, S., Doppler, E., Novak, P., et al. (2011). Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer’s disease. Journal of Neuroscience Research, 89, 1812–1821.

Shimada, H., Makizako, H., Doi, T., Yoshida, D., Tsutsumimoto, K., Anan, Y., et al. (2014). A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly. Frontiers in Aging Neuroscience, 6, 69.

Sibille, E. (2013). Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders. Dialogues in Clinical Neuroscience, 15, 53–65.

Teixeira, A. L., Barbosa, I. G., Diniz, B. S., & Kummer, A. (2010). Circulating levels of brain-derived neurotrophic factor: Correlation with mood, cognition and motor function. Biomarkers in Medicine, 4, 871–887.

Weinstein, G., Beiser, A. S., Choi, S. H., Preis, S. R., Chen, T. C., Vorgas, D., et al. (2014). Serum brain-derived neurotrophic factor and the risk for dementia: The Framingham heart study. JAMA Neurolology, 71, 55–61.

Yu, H., Zhang, Z., Shi, Y., Bai, F., Xie, C., Qian, Y., et al. (2008). Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. Journal of Clinical Psychiatry, 69, 1104–1111.